Additionally, the type II topoisomerase inhibitor mitoxantrone inhibits USP11 and demonstrates increased progression-free and overall survival in a relapsed T-ALL clinical trial, suggesting that USP11 inhibition can be exploited therapeutically [14, 15]. This evidence concerns the gene USP11 and acute lymphoblastic leukemia.